Literature DB >> 31451965

Treatment Failure of Isavuconazole in a Patient with Cryptococcosis.

Kathleen A Linder1,2, Tejal N Gandhi1, Marisa H Miceli3.   

Abstract

Isavuconazole is a broad-spectrum azole that is FDA-approved for the treatment of aspergillosis and mucormycosis; data on the use of isavuconazole for the treatment and prevention of other invasive fungal infections are limited. Here, we report a patient with pulmonary cryptococcosis treated with isavuconazole who experienced progression to disseminated infection with Cryptococcus while on isavuconazole. Caution is advised when using isavuconazole in situations where there is a paucity of data to recommend its use.

Entities:  

Keywords:  Cryptococcus; Isavuconazole; Treatment failure

Mesh：

Substances：

Year:  2019        PMID： 31451965     DOI： 10.1007/s11046-019-00374-3

Source DB:  PubMed          Journal:  Mycopathologia        ISSN： 0301-486X            Impact factor:   2.574


  16 in total

1.  The Curious Case of "Case Report" of Infections Caused by Human and Animal Fungal Pathogens: An Educational Tool, an Online Archive, or a Format in Need of Retooling.

Authors:  Jean-Philippe Bouchara; Vishnu Chaturvedi
Journal:  Mycopathologia       Date:  2018-12       Impact factor: 2.574

2.  Isavuconazole activity against Aspergillus lentulus, Neosartorya udagawae, and Cryptococcus gattii, emerging fungal pathogens with reduced azole susceptibility.

Authors:  K Datta; P Rhee; E Byrnes; G Garcia-Effron; D S Perlin; J F Staab; K A Marr
Journal:  J Clin Microbiol       Date:  2013-06-26       Impact factor: 5.948

3.  Serial monitoring of isavuconazole blood levels during prolonged antifungal therapy.

Authors:  E Furfaro; A Signori; C Di Grazia; A Dominietto; A M Raiola; S Aquino; C Ghiggi; A Ghiso; R Ungaro; E Angelucci; C Viscoli; M Mikulska
Journal:  J Antimicrob Chemother       Date:  2019-08-01       Impact factor: 5.790

4.  Multicenter study of isavuconazole MIC distributions and epidemiological cutoff values for the Cryptococcus neoformans-Cryptococcus gattii species complex using the CLSI M27-A3 broth microdilution method.

Authors:  A Espinel-Ingroff; A Chowdhary; G M Gonzalez; J Guinea; F Hagen; J F Meis; G R Thompson; J Turnidge
Journal:  Antimicrob Agents Chemother       Date:  2014-10-13       Impact factor: 5.191

5.  Practice Guidelines for the Diagnosis and Management of Aspergillosis: 2016 Update by the Infectious Diseases Society of America.

Authors:  Thomas F Patterson; George R Thompson; David W Denning; Jay A Fishman; Susan Hadley; Raoul Herbrecht; Dimitrios P Kontoyiannis; Kieren A Marr; Vicki A Morrison; M Hong Nguyen; Brahm H Segal; William J Steinbach; David A Stevens; Thomas J Walsh; John R Wingard; Jo-Anne H Young; John E Bennett
Journal:  Clin Infect Dis       Date:  2016-06-29       Impact factor: 9.079

6.  Antifungal susceptibility patterns of a global collection of fungal isolates: results of the SENTRY Antifungal Surveillance Program (2013).

Authors:  Mariana Castanheira; Shawn A Messer; Paul R Rhomberg; Michael A Pfaller
Journal:  Diagn Microbiol Infect Dis       Date:  2016-02-09       Impact factor: 2.803

7.  Breakthrough candidaemia caused by phenotypically susceptible Candida spp. in patients with haematological malignancies does not correlate with established interpretive breakpoints.

Authors:  Maria N Gamaletsou; George L Daikos; Thomas J Walsh; David S Perlin; Cristina Jimenez Ortigosa; Anna Psaroulaki; Maria Pagoni; Athina Argyropoulou; Martha Nepka; Efstathia Perivolioti; Maria Kotsopoulou; Stavroula Perloretzou; Markos Marangos; Diamantis Kofteridis; Maria Grammatikou; Dimitrios Goukos; George Petrikkos; Nikolaos V Sipsas
Journal:  Int J Antimicrob Agents       Date:  2014-06-30       Impact factor: 5.283

8.  Breakthrough Fungal Infections in Patients With Leukemia Receiving Isavuconazole.

Authors:  Caitlin R Rausch; Adam J DiPippo; Prithviraj Bose; Dimitrios P Kontoyiannis
Journal:  Clin Infect Dis       Date:  2018-10-30       Impact factor: 9.079

9.  Clinical practice guidelines for the management of cryptococcal disease: 2010 update by the infectious diseases society of america.

Authors:  John R Perfect; William E Dismukes; Francoise Dromer; David L Goldman; John R Graybill; Richard J Hamill; Thomas S Harrison; Robert A Larsen; Olivier Lortholary; Minh-Hong Nguyen; Peter G Pappas; William G Powderly; Nina Singh; Jack D Sobel; Tania C Sorrell
Journal:  Clin Infect Dis       Date:  2010-02-01       Impact factor: 9.079

10.  Isavuconazole Treatment of Cryptococcosis and Dimorphic Mycoses.

Authors:  George R Thompson; Adrian Rendon; Rodrigo Ribeiro Dos Santos; Flavio Queiroz-Telles; Luis Ostrosky-Zeichner; Nkechi Azie; Rochelle Maher; Misun Lee; Laura Kovanda; Marc Engelhardt; Jose A Vazquez; Oliver A Cornely; John R Perfect
Journal:  Clin Infect Dis       Date:  2016-05-11       Impact factor: 9.079
View more
  1 in total

Review 1.  Drug-Resistant Fungi: An Emerging Challenge Threatening Our Limited Antifungal Armamentarium.

Authors:  Amir Arastehfar; Toni Gabaldón; Rocio Garcia-Rubio; Jeffrey D Jenks; Martin Hoenigl; Helmut J F Salzer; Macit Ilkit; Cornelia Lass-Flörl; David S Perlin
Journal:  Antibiotics (Basel)       Date:  2020-12-08
  1 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.